Literature DB >> 1318169

Doxorubicin inhibits human DNA topoisomerase I.

P D Foglesong1, C Reckord, S Swink.   

Abstract

Purified human DNA topoisomerase I was assayed quantitatively by enzyme titrations with supercoiled pHC624 DNA in the presence of 0-2.0 microM doxorubicin. Supercoiled and relaxed DNAs were resolved by agarose gel electrophoresis in the presence of ethidium bromide, and the percentage of conversion of supercoiled DNA to relaxed DNA was quantified by scanning microdensitometry. The inhibition of DNA topoisomerase I activity was measured at varying concentrations of doxorubicin. Doxorubicin inhibited enzyme activity at an IC50 value (the concentration required to inhibit 50% of the total activity) of 0.8 microM. Similar inhibition was observed for daunomycin, a structurally related anthracycline antitumor drug. These results indicate that anthracyclines inhibit human DNA topoisomerase I activity at concentrations that cause DNA damage and cytotoxicity in vivo.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1318169     DOI： 10.1007/bf00686403

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  18 in total

1.  Mitochondria contain a distinct DNA topoisomerase.

Authors:  F R Fairfield; W R Bauer; M V Simpson
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

2.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.

Authors:  Y Sugimoto; S Tsukahara; T Oh-hara; T Isoe; T Tsuruo
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 3.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

4.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.

Authors:  S P Cole; E R Chanda; F P Dicke; J H Gerlach; S E Mirski
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

5.  Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.

Authors:  A M Deffie; J K Batra; G J Goldenberg
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

6.  Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

Authors:  R S Gupta; R Gupta; B Eng; R B Lock; W E Ross; R P Hertzberg; M J Caranfa; R K Johnson
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

7.  Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

Authors:  K Wassermann; J Markovits; C Jaxel; G Capranico; K W Kohn; Y Pommier
Journal:  Mol Pharmacol       Date:  1990-07       Impact factor: 4.436

8.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

9.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

10.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162
View more
  19 in total

1.  The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

Authors:  Lynda M Vrooman; Donna S Neuberg; Kristen E Stevenson; Barbara L Asselin; Uma H Athale; Luis Clavell; Peter D Cole; Kara M Kelly; Eric C Larsen; Caroline Laverdière; Bruno Michon; Marshall Schorin; Cindy L Schwartz; Harvey J Cohen; Steven E Lipshultz; Lewis B Silverman; Stephen E Sallan
Journal:  Eur J Cancer       Date:  2011-04-20       Impact factor: 9.162

2.  Acetylation dynamics of human nuclear proteins during the ionizing radiation-induced DNA damage response.

Authors:  Martin V Bennetzen; Dorthe Helena Larsen; Christoffel Dinant; Sugiko Watanabe; Jiri Bartek; Jiri Lukas; Jens S Andersen
Journal:  Cell Cycle       Date:  2013-05-01       Impact factor: 4.534

3.  Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.

Authors:  Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; Sunil Martin; James L Riley; James T Kurnick
Journal:  Cancer Immunol Immunother       Date:  2010-10-30       Impact factor: 6.968

4.  Characterization of alkylating versus intercalating anticancer drug-induced effects on cell survival, cell cycle kinetic and morphonuclear pattern of three neoplastic cells lines growing in vitro.

Authors:  O Pauwels; R Kiss; J L Pasteels; G Atassi
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

Review 5.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

6.  Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide.

Authors:  J Damrot; T Nübel; B Epe; W P Roos; B Kaina; G Fritz
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

Review 7.  Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.

Authors:  Kristopher A Sarosiek; Anthony Letai
Journal:  FEBS J       Date:  2016-10       Impact factor: 5.542

8.  On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.

Authors:  Marina Gálvez-Peralta; Jennifer S Hackbarth; Karen S Flatten; Scott H Kaufmann; Hiroshi Hiasa; Chenguo Xing; David M Ferguson
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

Review 9.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

10.  Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.

Authors:  Allan D Heibein; Baoqing Guo; Jason A Sprowl; David A Maclean; Amadeo M Parissenti
Journal:  BMC Cancer       Date:  2012-08-31       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.